High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer

Autor: Bengt Glimelius, Halfdan Sorbye, Fredrik Pontén, Camilla Qvortrup, Jakob Eberhard, Anca Dragomir, Per Pfeiffer, Karin Jirström, Christina Siesing
Rok vydání: 2017
Předmět:
Male
0301 basic medicine
Oncology
Organoplatinum Compounds
Colorectal cancer
Treatment outcome
Cancer Treatment
lcsh:Medicine
Improved survival
Kaplan-Meier Estimate
0302 clinical medicine
Medicine and Health Sciences
Neoplasm Metastasis
lcsh:Science
Staining
Multidisciplinary
Clinical Laboratory Medicine
Pharmaceutics
RNA-Binding Proteins
Prognosis
Immunohistochemistry
Oxaliplatin
Klinisk laboratoriemedicin
Surgical Oncology
Treatment Outcome
030220 oncology & carcinogenesis
Female
Colorectal Neoplasms
Research Article
medicine.drug
Clinical Oncology
medicine.medical_specialty
Disease free survival
Surgical and Invasive Medical Procedures
Research and Analysis Methods
Disease-Free Survival
Cancer Chemotherapy
03 medical and health sciences
Drug Therapy
Internal medicine
medicine
Chemotherapy
Humans
In patient
Immunohistochemistry Techniques
Cytoplasmic Staining
Aged
Proportional Hazards Models
Colorectal Cancer
Cell Nucleus
Cancer och onkologi
Proportional hazards model
business.industry
lcsh:R
Cancers and Neoplasms
medicine.disease
Histochemistry and Cytochemistry Techniques
030104 developmental biology
Specimen Preparation and Treatment
Cancer and Oncology
Immunologic Techniques
lcsh:Q
Clinical Medicine
business
Zdroj: PLoS ONE, Vol 12, Iss 8, p e0182512 (2017)
PLoS ONE
Siesing, C, Sorbye, H, Dragomir, A, Pfeiffer, P, Qvortrup, C, Pontén, F, Jirström, K, Glimelius, B & Eberhard, J 2017, ' High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer ', PLOS ONE, vol. 12, no. 8, e0182512 . https://doi.org/10.1371/journal.pone.0182512
ISSN: 1932-6203
Popis: Background: High expression of the RNA-binding motif protein 3 (RBM3) has been shown to correlate, with prolonged survival in several malignant diseases and with the benefit of platinum-based chemotherapy in ovarian cancer. The aim of this study was to evaluate RBM3 in metastatic colorectal cancer (mCRC) as a prognostic factor for overall survival and in relation to benefit of first-line chemotherapy. Methods: Immunohistochemical staining was conducted and evaluated in tumours from 455 mCRC patients. Kaplan-Meier analysis and Cox regression proportional hazards models were used to access the impact of RBM3 expression on overall survival (OS) and progression-free survival (PFS). Results: High RBM3 expression, both nuclear and cytoplasmic, was an independent prognostic factor for prolonged OS (hazard ratio [HR] 0.67, 95% confidence interval [CI] 0.50–0.90 and HR 0.66, 95% CI 0.48–0.91, respectively). PFS was significantly longer in patients with high RBM3 expression who had received first-line oxaliplatin based treatment, compared to those who had received irinotecan based treatment, both regarding nuclear and cytoplasmic expression (p-value 0.020 and 0.022 respectively). Conclusion: High RBM3 expression is an independent predictor of prolonged survival in mCRC patients, in particular in patients treated with first-line oxaliplatin based chemotherapy.
Databáze: OpenAIRE
Externí odkaz: